Category: Press Release

CQDM partners with GlycoNet to support innovative Glycomics research in Canada

CQDM partners with GlycoNet to support innovative Glycomics research in Canada

The partnership will support the development of novel technologies in drug discovery, accelerate scientific talents across Canada, and advance Canada’s position as an international leader for healthcare innovation.

GlycoNet awards $1.45 million to eight projects aimed at improving the health of Canadians

GlycoNet awards $1.45 million to eight projects aimed at improving the health of Canadians

GlycoNet awards $1.45 million to eight projects aimed at improving the health of Canadians. Funding supports glycomics translational research into post-surgical pain management, cancer diagnosis, and treatment of Parkinson’s disease, infectious diseases and chronic illness.

GlycoNet awards grants worth $90,000 to three Alberta startup companies

GlycoNet awards grants worth $90,000 to three Alberta startup companies

Glyco-based companies use funds to protect intellectual property, build business capacity EDMONTON (October 9, 2018) – The Canadian Glycomics Network (GlycoNet) awarded $90,000 in grants to three Alberta-based startup companies: 48Hour Discovery Inc., GlyCa BioSciences Inc. and PanTHERA CryoSolutions Inc. The Startup Company Funding Program recognizes the needs of start-up companies and provides financial help […]

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery

Precision Therapeutics Subsidiary, TumorGenesis, Announces License Agreement with 48Hour Discovery

MINNEAPOLIS, March 15, 2018 (GLOBE NEWSWIRE) — Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), formerly Skyline Medical, announced today that its wholly owned subsidiary, TumorGenesis Inc., has secured a license agreement with 48Hour Discovery (“48HD”) which grants it access to 48HD’s ligand discovery technology. This follows a license agreement with SyntArray, LLC, announced on March 13th, and […]

en_USEnglish
fr_CAFrench en_USEnglish
Scroll to Top